Foundayoâ„¢ Launch Impact on Eli Lilly: Prescriptions & LLY Stock Fall

About Eli Lilly and Company

The Foundayo launch impact on Eli Lilly has been swift and sharp — while FDA approval of orforglipron marked a historic first for oral GLP-1 obesity treatment, early prescription data trailing Novo Nordisk’s Wegovy sent LLY stock down as much as 4.3%, forcing analysts to slash 2026 revenue forecasts from $5 billion to just $1.3–1.6 billion.

Novo Nordisk Announces Positive Topline Results for Oral Semaglutide for Type 2 Diabetes in Children

novo nordisk

Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.

Tzield FDA Approval for Young Children: Sanofi Expands Life-Changing T1D Therapy

sanofi

Sanofi has achieved a historic breakthrough with the expanded Tzield FDA approval for young children. Previously restricted to those aged eight and older, the therapy is now available for children as young as one year old, offering a vital window to delay the onset of clinical Type 1 Diabetes.